Latest Headlines

Latest Headlines

Bullish ex-Elan chief plots a $43M buy-in for upstart Serenus

Fresh from floating plans to raise up to $364 million in an IPO for his life sciences fund, ex-Elan chief Kelly Martin is going into the biopharma business with his former chief medical officer, Menghis Bairu. Martin announced today that he's sinking up to $43 million into Bairu's newborn Serenus Biotherapeutics with plans to gain a majority interest in the company.

Ex-Elan execs target €325M IPO for life science fund

Former Elan CEO Kelly Martin and other people with links to the Irish drugmaker are aiming to raise up to €325 million ($364 million) in an IPO to bankroll their life science investment fund. The IPO on the Irish Stock Exchange could dwarf last year's listing by Circassia and become one of the biggest floats in European biotech history.

Dublin-based Perrigo could be up next for a tax-inversion deal

OTC generics maker Perrigo could be the next tax-advantaged company in line for a buyout. And while Perrigo hasn't confirmed any M&A plans, speculation has been enough to send shares soaring.

'Doctor-2' in Elan, Wyeth insider trading case said to be well-connected Alzheimer's doc

In court documents he is identified only as doctor No. 2. But sources say that it was a prominent and trusted New Jersey doctor and Alzheimer's researcher for an Elan drug candidate who was the second tell-all source for an alleged massive insider trading deal, one of a number of cases authorities are pursuing.

UPDATED: SAC fund manager alleged to have not 1 but 2 docs feeding him insider info

A so-called superseding federal indictment today says former hedge fund trader Mathew Martoma, accused of insider trading in Elan and Wyeth stock,  had not one but two doctors giving him the inside scoop that allowed his hedge fund to record more than $275 million in profits and losses avoided.

Will the biotech dealmaking lull extend through the rest of the year?

PricewaterhouseCoopers has been running the numbers on deals and dollars in the biopharma industry. And the big accounting firm is echoing a growing lineup of analysts who see that dealmaking in the industry is suffering even as IPOs are booming. But easy access to cash could change things around dramatically in the second half of this year.

Biotech dealmaking pace slows, but PhII remains popular

Looking over the 416 licensing deals EvaluatePharma tracked for the first six months of the year, total upfronts and deal values for Phase II programs were well ahead of Phase III--as well as the pace set for mid-stage pacts in the first half of 2012.

Deal buzz: Alkermes, Jazz Pharma could beckon buyers in Irish tax haven

For some pharma dealmakers, corporate domiciles in Ireland have become hot commodities. The Irish tax code figured prominently in two recent biopharma buyout deals, and, as Bloomberg reports, this makes the biotech group Alkermes and Jazz Pharmaceuticals potential targets.

OTC specialist Perrigo nabs Elan and its tax rate for $8.6B

Perrigo has snatched up Elan for $8.6 billion in a cash-and-stock deal. Call it a case of opposites attracting: U.S.-based Perrigo specializes in cheap, store-brand generics, while Elan is an Irish biotech best know for its longstanding--and now dissolved--partnership with Biogen Idec on the multiple sclerosis drug Tysabri.

UPDATED: Perrigo targets Ireland tax perks in $8.6B Elan buyout

The chase for Elan appears to be over. Perrigo, a U.S. maker of over-the-counter and generic drugs, has emerged with a winning bid to acquire the Irish biotech outfit for $8.6 billion in cash and stock.